Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

Next Previous
X
Search
Trial Profile

Phase I Trial of Systemic Administration of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon, in Patients With Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, Lymphomas, or Histiocytic/Dendritic Cell Neoplasms

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Apr 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs VSV-IFNbeta-NIS (Primary) ; Cemiplimab; Cyclophosphamide; Ipilimumab; Nivolumab; Ruxolitinib
  • Indications Acute myeloid leukaemia; Anaplastic large cell lymphoma; B-cell lymphoma; Cutaneous T-cell lymphoma; Multiple myeloma; Mycosis fungoides; Peripheral T-cell lymphoma; T-cell lymphoma
  • Focus Adverse reactions; First in man

    • Most Recent Events

    • 28 Mar 2024 Planned End Date changed from 1 Dec 2024 to 1 Apr 2032.
    • 28 Mar 2024 Planned primary completion date changed from 1 Dec 2024 to 31 Dec 2028.
    • 06 Feb 2024 Number of treatment arms increased from 3 to 4 by the addition of Experimental: Group D (VSV-IFNbeta-NIS, ruxolitinib, cemiplimab) arm, thus adding Cemiplimab also to the treatment regimen.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top